Q3 2021 Investor Relations Results slide image

Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Oncology: Solid Tumors 104 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine
View entire presentation